No Data
Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Shares Bounce 43% But Its Business Still Trails The Market
Should You Be Adding Shanghai Allist Pharmaceuticals (SHSE:688578) To Your Watchlist Today?
Jiakangsi-B (01167.HK): The company received the first payment for the exclusive license agreement with shanghai allist pharmaceuticals co., ltd. on GLECIRASIB and JAB-3312, as well as partial compensation for research and development expenses and other p
Grants of September 27th, Akesi-B (01167.HK) announced an exclusive license agreement with shanghai allist pharmaceuticals co., ltd. for Glecirasib and JAB-3312. The Company's subsidiary, Beijing Akesi New Drug Development Co., Ltd. (an indirectly-held non-wholly-owned subsidiary of the Company), has received an amount of approximately RMB 0.173 billion on August 30, 2024 from shanghai allist pharmaceuticals co., ltd. for the external license agreement on KRAS G12C inhibitor Glecirasib (JAB-21822) and SHP2 variant inhibitor JAB-3312, including an initial payment.
Abbisko Cayman NSCLC Drug Gets NMPA's Approval for Clinical Trials
Shanghai Allist Pharmaceuticals Gets China Nod for Non-Small-Cell Lung Cancer Tablet Clinical Trials
shanghai allist pharmaceuticals co., ltd. (688578.SH): AST2303 tablets obtained a drug clinical trial approval notice.
Gelonghui September 23rd | Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) announced that it has recently received the approval letter of "Clinical Trial Approval Notice for Pharmaceutical Products" issued by the National Medical Products Administration, allowing the clinical trial of AST2303 tablets in adult patients with advanced non-small cell lung cancer carrying the EGFRC797S mutation. AST2303 tablet (ABK3376 tablet) is a highly selective, brain-penetrant new generation EGFR oral small molecule inhibitor that can effectively inhibit the EGFRC797S mutation.
Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Shareholders Might Be Looking For ExitNo Data
No Data
